Spots Global Cancer Trial Database for post menopausal
Every month we try and update this database with for post menopausal cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| Observational Triveneto Study on the Use of Adjuvant Hormonal Therapies in the Treatment of Hormone-responsive Breast Cancer | NCT00884143 | Post Menopausal Breast Cancer | - | AstraZeneca | ||
| AKT Inhibitor in Oestrogen Positive Breast Cancer | NCT02077569 | Invasive Breast... | AZD5363 | 18 Years - | University of Nottingham | |
| AKT Inhibitor in Oestrogen Positive Breast Cancer | NCT02077569 | Invasive Breast... | AZD5363 | 18 Years - | University of Nottingham | |
| Breast Cancer Tumor Care Observational Programme | NCT00660244 | Post Menopausal Arthralgia | anastrozole | - | AstraZeneca | |
| Observational Triveneto Study on the Use of Adjuvant Hormonal Therapies in the Treatment of Hormone-responsive Breast Cancer | NCT00884143 | Post Menopausal Breast Cancer | - | AstraZeneca | ||
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer | NCT01808040 | Post Menopausal... | TAK700 | 18 Years - | University of Wisconsin, Madison | |
| Effects of Aromatase Inhibitor Therapy on Muscle Function | NCT03581552 | Breast Cancer Breast Cancer F... | 18 Years - | Indiana University | ||
| Breast Cancer Tumor Care Observational Programme | NCT00660244 | Post Menopausal Arthralgia | anastrozole | - | AstraZeneca | |
| A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer | NCT01808040 | Post Menopausal... | TAK700 | 18 Years - | University of Wisconsin, Madison | |
| A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors | NCT02743637 | Advanced Malign... Advanced Solid ... Neoplasm Metastasis | SDX-7320 | 21 Years - 85 Years | SynDevRx, Inc. | |
| Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | NCT03176238 | Post Menopausal... | everolimus exemestane | 18 Years - | Novartis | |
| Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | NCT03176238 | Post Menopausal... | everolimus exemestane | 18 Years - | Novartis | |
| Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women | NCT02400567 | Neoadjuvant Ope... | Fluorouracile Epirubicin Cyclophosphamid... Letrozole Palbociclib | 18 Years - | UNICANCER | |
| Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | NCT03176238 | Post Menopausal... | everolimus exemestane | 18 Years - | Novartis | |
| A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer | NCT01808040 | Post Menopausal... | TAK700 | 18 Years - | University of Wisconsin, Madison | |
| A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors | NCT02743637 | Advanced Malign... Advanced Solid ... Neoplasm Metastasis | SDX-7320 | 21 Years - 85 Years | SynDevRx, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
